ADVENTRX (NYSE: ANX), a San Diego-based biopharmaceutical company, has made some strides in the development of a product candidate designed to treat genetic hematoma disorders, specifically sickle cell anemia (SCA), an orphan drug market with implications for millions of people.
September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.
A crescent moon is never as fulfilling as a full moon and now a new drug seeks to find a way to turn a crescent full again.
The Newton, Mass.-based biopharmaceutical company is developing a small-molecule drug for sickle cell disease.
Copyright © 2024 | WordPress Theme by MH Themes